RNA-Editing Enzyme May be a Novel Treatment Target in Parkinson’s

A recent study has identified a new layer in the complex biology of Parkinson’s disease. Researchers found that a process called RNA editing in astrocytes—the support cells that help keep nerve cells healthy—may play a role in the brain inflammation seen in Parkinson’s. This inflammation could contribute to the gradual loss of brain cells involved in movement and coordination. What Triggers This Change? The changes in RNA editing seem to be triggered by alpha-synuclein, a protein that tends to clump together in the brains of people with Parkinson’s. These clumps can disrupt normal brain function and are a hallmark of the condition. Understanding RNA Editing and ADAR1 RNA editing is a natural process that slightly alters genetic messages before they are used to make proteins. One important enzyme in this process is ADAR1, which helps regulate immune responses in the brain. The study found that in Parkinson’s, ADAR1 becomes more active in astrocytes and may cause these cells to enter a prolonged, inflammatory state. Study Approach: Using Human-Derived Brain Cells Researchers from KAIST (South Korea), University College London, and The Francis Crick Institute used human stem cell technology to create brain cells in the lab. They exposed these cells to toxic forms of alpha-synuclein and observed changes in gene activity, particularly related to immune and inflammatory responses. Inflammation and Cell Death Astrocytes exposed to alpha-synuclein showed increased inflammation and released inflammatory molecules. This environment was harmful to neurons, leading to increased cell death. The enzyme ADAR1 was more active under these conditions, potentially linking it to both inflammation and neuron loss. Why This Matters This discovery suggests that targeting RNA editing—specifically the activity of ADAR1—might offer a completely new approach to treating Parkinson’s disease, focused on reducing harmful inflammation in the brain rather than just managing symptoms. A Hopeful Direction for the Future While more research is needed, this study highlights how looking at Parkinson’s from different biological angles—like inflammation and genetic regulation—could open up new possibilities for treatment.